A Randomized, Controlled Study Evaluating the Efficacy and Safety of GS-1101 (CAL-101) in Combination With Ofatumumab for Previously Treated Chronic Lymphocytic Leukemia
by on Tuesday, August 7th, 2012 | No Comments
Condition: Chronic Lymphocytic Leukemia
Interventions: Drug: Ofatumumab (1000 mg dosing regimen); Drug: GS-1101; Drug: Ofatumumab (2000 mg dosing regimen)
Sponsors: Gilead Sciences; Gilead Sciences
Not yet recruiting – verified August 2012
See original here: A Randomized, Controlled Study Evaluating the Efficacy and Safety of GS-1101 (CAL-101) in Combination With Ofatumumab for Previously Treated Chronic Lymphocytic Leukemia